Sign In to Follow Application
View All Documents & Correspondence

Microarray Based Analysis Of Polynucleotide Sequence Variations

Abstract: Solid phase polymerase-mediated amplification approaches using immobilized primers on a microarray are provided for detecting sequence variations in a target polynucleotide. The methods and compositions provided herein are useful for research and clinical applications, particularly for large scale assays of genetic information in biological samples of interest.

Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence

Patent Information

Application #
Filing Date
21 November 2001
Publication Number
35/2016
Publication Type
INA
Invention Field
BIOTECHNOLOGY
Status
Email
Parent Application

Applicants

MERGEN LTD.
14826, WICKS BOULEVARD, SAN LEANDRO CA

Inventors

1. YU ZALIN
2374 BEL VEDERE AVENUE, SAN-LEANDRO, CALIFORNIA 94577
2. PENG ZAOYUAN
865 SAN JUDE STREET PALO ALTO, CALIFORNIA 94396
3. HU QIANJIN
20499 CROW CREEK ROAD, CASTRO VALLEY CALIFORNIA 94552

Specification

MICROARRAY-BASED ANALYSIS OF
POLYNUCLEOTIDE SEQUENCE VARIATIONS
CROSS REFERENCE TO RELATED APPLICATIONS
This Application claims priority of provisional application number 60/191,356 filed
March 22,2000.
TECHNICAL FIELD OF THE INVENTION
This invention relates generally to the field of nucleic acid biology. More
specifically, the invention provides methods and compositions for high-throughput
amplification, detection and comparison of polynucleotide sequence variations in
biological samples for research, diagnostic and therapeutic applications.
BACKGROUND OF THE INVENTION
As the Human Genome Project approaches completion of a reference sequence of
the human genome, increasing attention is being paid to uncovering DNA sequence
variations among groups of individuals as well as between different human populations.
Identifying these variations is a critical part of further exploration of the genetic basis for
predisposition and resistance to disease. These sequence variations will serve as genetic
markers in studies of diseases and traits with complex inheritance patterns and strong
environmental interactions.
Currently, large-scale sequence assays for population-based genetic variations such
as single nucleotide polymorphisms (SNPs) are done on hybridization-based
oligonucleotide arrays (DNA chips). For example, U.S. Patent 5,837,832 (Chee et al.)
describes DNA chips containing arrays of four sets of probes, each of which differs from
others on a single nucleotide. Target polynucleotides of interest are hybridized to the DNA
chip and the specific sequence variations detected based on the target polynucleotides'
preference and degree of hybridization at discrete probe locations. Similar technology was
used in U.S. Patent 5,861,242 (Chee et al.) for analysis of various HTV DNA sequences.
Several problems are associated with the current hybridization-based sequence
variation assays, and hence limiting their applications. See review by Hacia (1999) Nature
Genetics Supp. 21:42-47. For example, accuracy of the hybridization assay remains poor,
which hinders its use in heterozygous mutation screens. The same experimental approach
applied to any two sequences can yield results with vastly different accuracy. The false
negative error rate of the hybridization-based mutational analysis needs to be improved.
Since the hybridization-based methodology is hinged on the hybridization differences by .
one nucleotide, the specificity of hybridization-based sequence analysis can be dramatically
influenced by variations in target polynucleotide as well as in hybridization conditions.
Hybridization-based mutation detection is particularly powerless when the target
polynucleotides are in trace amount in the sample.
Detection of small quantities of genetic materials represents a major challenge in
biological research and clinical diagnosis. Polymerase chain reaction (PCR) provides a
powerful tool for in vitro amplification of specific polynucleotide sequences, such as
genomic DNA, single stranded cDNA or mRNA, with high sensitivity and specificity. One
application of this is the amplification of target gene sequences in biological samples from,
for example, environmental, food and medical sources, etc. to allow identification of
causative, pathogenic, spoilage or indicator organisms present in the sample.
Therefore, there exist a need for developing methods for analyzing sequence
variations with higher accuracy and greater sensitivity.
SUMMARY OF THE INVENTION
The present invention provides novel methods for sequence variation analysis with
greater sensitivity, better accuracy and less time-consurning, as compared to the
conventional hybridization-based approaches.
In one aspect, the invention provides methods for detecting sequence variations
between a target polynucleotide and a reference sequence, including single or multiple base
substitutions, deletions or insertions, and other more complex variations. The methods
utilize an array of multiple groups of oligonucleotide primers immobilized to a solid phase
support, with each group of oligonucleotide primers being selected to span a particular
region of the reference sequence, occupying a discrete area of the array, and comprising at
least four sets of primers: 1) a first set that is exactly complementary to the reference
sequence; and 2) three additional sets of primers, each of which is identical to the first set
of primers but for the most 3'- end nucleotide which is different in each of the three sets.
The array of the invention can be used in a polymerase-mediated amplification reaction,
during which the target polynucleotide serves as template for the synthesis of detectable
nascent polynucleotides which are extended from the appropriate sets of primers that are
exactly complementary to the target polynucleotide. The immobilized primers enable "in-
situ" hybridization and amplification of specific regions of the target polynucleotide on a
solid-phase support. The nascent strand at each primer site can be detected quantitatively
with labels that are incorporated into the strand during amplification. In one preferred
embodiment, the amplification means for practicing the invention is PCR. The microarray
on a solid phase support can comprise up to about 100,000 groups of primers. As such, the
method is useful for detecting up to about 100,000 different regions of the target
polynucleotide. For most applications, a high number of groups will be desirable, although
it is clear that there is no lower limit to the number of groups which can be present on the
support.
According to one embodiment of the invention, an immobilized primer is used
alone for asymmetric PCR of a target polynucleotide that will result in a single
complementary strand attached to the solid phase at each proper primer site and detected
optionally with labels incorporated into the strand. According to another embodiment of the
invention, another primer for each target polynucleotide is present in solution so that both
strands for a target polynucleotide can be symmetrically synthesized and retained at each
primer site for enhanced detection.
The present invention can be used to detect sequence variations in a single target
polynucleotide as compared with a reference sequence, in which case the DNA array of the
invention comprises multiple groups of primers corresponding and or relating to the
reference sequence, as described above. Alternatively, the invention can be used to detect
sequence variations in multiple target polynucleotides as compared with one or many
reference sequences. The target polynucleotides can be structurally related or unrelated.
When multiple target polynucleotides with no sequence homology are detected according
to the present invention, the DNA microarray is divided into different areas with each area
devoted to a particular reference sequence aimed at a particular target polynucleotide.
Multiple groups of primers are affixed onto the solid support within the area, with each
group being selected to span a particular region of the reference sequence. As in the case of
single target polynucleotide, each group comprises at least four sets of primers: 1) a first set
that is exactly complementary to the reference sequence; and 2) three additional sets of
primers, each of which is identical to the first set of primers but for the most 3'- end
nucleotide which is different in each of the three sets.
The invention further provides kits for detecting sequence variations in a target
polynucleotide using either symmetric PCR or asymmetric PCR approach as disclosed
herein. The kits comprise a microarray of PCR primers and reagents necessary for PCR
reaction and detection. The microarray of primers can comprise up to about 100,000 groups
of primers tailored to particular reference sequences. In one embodiment of the invention,
the kits comprise labeled nucleotides capable of being incorporated into the synthesized
strands during PCR reaction.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 depicts schematically a solid phase amplification methods for amplifying
and detecting sequence variations in a target polynucleotide, using immobilized primers.
Figure 2 shows the results of solid phase amplification of human G3PDF gene
templates using four sets of primers having one nucleotide difference at the 3'-end.
MODE(S) FOR CARRYING OUT THE INVENTION
The present invention provides novel methods and compositions for high-
throughput fashioned, sensitive yet simple amplification and detection of sequence
variations in a target polynucleotide. The invention can be used in various aspects of
genome analysis that finds utility in both basic biological research and medical diagnosis
and therapeutics.
The present invention is based on a novel combination of PCR and polynucleotide
array technology. The basic principle of the invention is that a single nucleotide mismatch
between a template and a corresponding primer's 3'-end is sufficient to prevent the
elongation of a nascent strand. Therefore, the target polynucleotide will only be amplified
at the site where the primer is a perfect match with the target sequence. Some aspects of the
primer preparation and PCR amplification procedures are similar to those described in a co-
pending U.S. Provisional Application 60/173,618 (filed December 29, 1999) and the U.S.
Patent 5,837,832 (Chee et al.), disclosures of which are incorporated herein by reference.
A. Definitions
A "polynucleotide" is a polymeric form of nucleotides of any length, either
ribonucleotides or deoxyribonucleotides. This term refers only to the primary structure of
the molecule. Thus, this term includes double- and single-stranded DNA and RNA. It also
includes known types of modifications, for example, labels which are known in the art,
methylation, "caps", substitution of one or more of the naturally occurring nucleotides with
an analog, internucleotide modifications such as, for example, those with uncharged
linkages (e.g., phosphorothioates, phosphorodithioates, etc.), those containing pendant
moieties, such as, for example proteins (including for e.g., nucleases, toxins, antibodies,
signal peptides, poly-L-lysine, etc.),those with intercalators (e.g., acridine, psoralen, etc.),
those containing chelators (e.g., metals, radioactive metals, etc.), those containing
alkylators, those with modified linkages (e.g., alpha anomeric nucleic acids, etc.), as well as
unmodified forms of the polynucleotide.
The term "primer", as used herein, refers to an oligonucleotide which is capable of
acting as a point of initiation of polynucleotide synthesis along a complementary strand
when placed under conditions in which synthesis of a primer extension product which is
complementary to a polynucleotide is catalyzed. Such conditions include the presence of
four different nucleotide triphosphates or nucleoside analogs and one or more agents for
polymerization such as DNA polymerase and/or reverse transcriptase, in an appropriate
buffer ("buffer" includes substituents which are cofactors, or which affect pH, ionic
strength, etc.), and at a suitable temperature. A primer must be sufficiently long to prime
the synthesis of extension products in the presence of an agent for polymerase. A typical
primer contains at least about 5 nucleotides in length of a sequence substantially
complementary to the target sequence, but somewhat longer primers are preferred. Usually
primers contain about 15-26 nucleotides, but longer primers, up to 35 nucleotides, may also
be employed.
A primer will always contain a sequence substantially complementary to the target
sequence, that is the specific sequence to be amplified, to which it can anneal. A primer
may, optionally, also comprise a promoter sequence. The term "promoter sequence"
defines a single strand of a nucleic acid sequence that is specifically recognized by an RNA
polymerase that binds to a recognized sequence and initiates the process of transcription by
which an RNA transcript is produced. In principle, any promoter sequence may be
employed for which there is a known and available polymerase that is capable of
recognizing the initiation sequence. Known and useful promoters are those that are
recognized by certain bacteriophage polymerases, such as bacteriophage T3, T7 or SP6.
As used herein, the term "tag," "sequence tag" or "primer tag sequence" refers to an
oligonucleotide with specific nucleic acid sequence that serves to identify a batch of
polynucleotides bearing such tags therein. Polynucleotides from the same biological source
are covalently tagged with a specific sequence tag so that in subsequent analysis the
polynucleotide can be identified according to its source of origin. The sequence tags also
serves as primers for nucleic acid amplification reactions.
A "microarray" is a linear or two-dimensional array of preferably discrete regions,
each having a defined area, formed on the surface of a solid support. The density of the
discrete regions on a microarray is determined by the total numbers of target
polynucleotides to be detected on the surface of a single solid phase support, preferably at
least about 50/cm2, more preferably at least about 100/cm2, even more preferably at least
about 500/cm2, and still more preferably at least about 1,000/cm2. As used herein, a DNA
microarray is an array of oligonucleotide primers placed on a chip or other surfaces used to
amplify or clone target polynucleotides. Since the position of each particular group of
primers in the array is known, the identities of the target polynucleotides can be determined
based on their binding to a particular position in the microarray.
A "linker" is a synthetic oligodeoxyribonucleotide which contains a restriction site.
A linker may be blunt end-ligated onto the ends of DNA fragments to create restriction
sites which can be used in the subsequent cloning of the fragment into a vector molecule.
The term "label" refers to a composition capable of producing a detectable signal
indicative of the presence of the target polynucleotide in an assay sample. Suitable labels
include radioisotopes, nucleotide chromophores, enzymes, substrates, fluorescent
molecules, chemiluminescent moieties, magnetic particles, bioluminescent moieties, and
the like. As such, a label is any composition detectable by spectroscopic, photochemical,
biochemical, immunochemical, electrical, optical or chemical means.
The term "support" refers to conventional supports such as beads, particles,
dipsticks, fibers, filters, membranes and silane or silicate supports such as glass slides.
The term "amplify" is used in the broad sense to mean creating an amplification
product which may include, for example, additional target molecules, or target-like
molecules or molecules complementary to the target molecule, which molecules are created
by virtue of the presence of the target molecule in the sample. In the situation where the
target is a nucleic acid, an amplification product can be made enzymatically with DNA or
RNA polymerases or reverse transcriptases.
As used herein, a "biological sample" refers to a sample of tissue or fluid isolated
from an individual, including but not limited to, for example, blood, plasma, serum, spinal
fluid, lymph fluid, the external sections of the skin, respiratory, intestinal, and
genitourinary tracts, tears, saliva, milk, cells (including but not limited to blood cells),
tumors, organs, and also samples of in vitro cell culture constituents.
The term "biological sources" as used herein refers to the sources from which the
target polynucleotides are derived from. The source can be of any form of "sample" as
described above, including but not limited to, cell, tissue or fluid. "Different biological
sources" can refer to different cells/tissues/organs of the same individual, or
cells/tissues/organs from different individuals of the same species, or cells/tissues/organs
from different species.
B. Selecting a Reference Sequence
The present invention can be used to compare a target polynucleotide with a
particular reference sequence. The target polynucleotide comprises either the reference
sequence itself or variants thereof. The sequence selected as a reference sequence can be
from any biological sources, including but not limited to cells, tissues or fluid. The
reference sequence and the target polynucleotide can be from different sources. Preferably,
the sources for the reference sequence and the target polynucleotide are from different
individuals of the same species, or different populations of the same species.
A reference sequence may contain at least a portion of a gene of interest from the
particular biological source. Preferably, the reference sequence for the present invention
covers a region in which at least one particular nucleotide position is known to be
associated with certain functionality of a gene. For example, the position can be an active
site of a gene encoding an enzyme, and a point mutation at the position causes the loss of
the enzymatic activity. The position can also be a drug resistance site in a bacteria genome,
at which a nucleotide substitution of the wild type gene causes the bacteria resistant to
certain antibiotics. The reference sequence may also contain the entire genome of the
biological source. For example, the entire genome of one HTV strain may be used as the
reference sequence for identification of sequence variants of different HTV strains.
The reference sequence can be from an individual representative of a particular
human population, and be used to identify SNPs of different populations. Different human
populations can be of different sex, age or race, can be from different geographic areas, and
can be from different families. Preferably, the reference sequences are selected to represent
certain identifiable traits or phenotypes of the population. Further studies on the association
of identified sequence variations and these phenotypic traits should provide insights in the
genetic linkage of the populations or genetic basis of certain diseases.
The reference sequence can be of any length, usually between about 5,10,20, 50,
100, 500,1000, 5000 or 10,000 bases. The reference sequence may contain some sequence
variations itself compared to a wild type gene, so long as the variations is outside of the
region of interest for the purpose of the present invention. The reference sequence can be
obtained from any sequence sources, such as sequence databases that are either publicly
accessible or commercially available.
C. Designing an Array of Oligonucleotide Primers
1. Selecting Primers
The invention provides a prepared solid support comprising immobilized and
separate groups of oligonucleotide primers. Each primer group corresponds to a particular
region within the reference sequence, and contains at least four sets of primers with the first
set being exactly complementary to the particular region of the reference sequence, and the
other three sets being identical to the first set but for the most 3'-end nucleotide. For
example, for an A nucleotide in the reference sequence, the corresponding primer from the
first set has a T at its most 3'-end, while the additional three primer sets have at their most
3'-end an A, C, or G, a different nucleotide in each set. The length of the four primer sets
are preferred, although not necessary, to be the same. The primers can be selected or
designed using for example a standard PCR primer selection program such as PrimerS from
Massachusetts Institute of Technology (MIT).
The solid phase support can provide an areas of about 5 to about 100 square
micrometers, on which up to about 100,000 groups of primers can be immobilized in
discrete areas according to a predetermined pattern. The prepared solid support can have an
associated written or electronic record of the sequence of the primer or primer pairs at any
given location on the support, and thus the location on the support of an amplified target
can be identified as well.
The number of primers within each group corresponding to a particular region of
the reference sequence can be determined and limited by the needs of the subsequent
planned amplification reaction on the microarray. Thus, for example, the number of
primers deemed necessary for conducting an PCR at a specific site on the microarray, given
especially the reaction volume and expected number of target template polynucleotide
molecules, and the proposed number of cycles of PCR, will help determine exactly how
much oligonucleotide primer copies to apply as a group at each location on the support to
ensure successful reactions. Preferably, the amounts of primers (i.e. primer molecule
numbers or primer concentration) will be about the same at each provided location on a
given solid support (e.g. in a DNA microarray format having from 1000, to 10,000, up to
about 100,000 groups of primers to amplify or detect up to about 100,000 regions of the
target polynucleotide).
The solid support can be prepared with primer sequences for a particular application
based on the polynucleotides to be detected. The oligonucleotide primers can be of any
length suitable for a particular PCR, especially considering the sequence and quality of the
target polynucleotides to be amplified. As an example, the primers can be from about 4 to
about 30 nucleotides in length.
It is understood that a nucleic acid primer of the present invention may contain
minor deletions, additions and/or substitutions of nucleic acid bases, to the extent that such
alterations do not negatively affect the yield or product obtained to a significant degree.
Oligonucleotide primers can include the naturally-occurring heterocyclic bases
normally found in nucleic acids (uracil, cytosine, thymine, adenine and guanine), as well as
modified bases and base analogues. Any modified base or base analogue compatible with
hybridization of the primer to a target sequence is useful in the practice of the invention.
The sugar or glycoside portion of the primer can comprise deoxyribose, ribose,
and/or modified forms of these sugars, such as, for example, 2'-0-alkyl ribose. In a
preferred embodiment, the sugar moiety is 2'-deoxyribose; however, any sugar moiety that
is compatible with the ability of the primer to hybridize to a target sequence can be used.
In one embodiment, the nucleoside units of the primer are linked by a
phosphodiester backbone, as is well known in the art. In additional embodiments,
internucleotide linkages can include any linkage known to one of skill in the art that is
compatible with specific hybridization of the primer including, but not limited to
phosphorothioate, methylphosphonate, sulfamate (e.g., U.S. Patent No. 5,470,967) and
polyamide (i.e., peptide nucleic acids). Peptide nucleic acids are described in Nielsen et al.
(1991) Science ISA: 1497-1500, U.S. Patent No. 5,714,331, and Nielsen (1999) Curr. Opin.
Biotechnol. 10:71-75.
In certain embodiments, the primer can be a chimeric molecule; i.e., can comprise
more than one type of base or sugar subunit, and/or the linkages can be of more than one
type within the same primer.
The primer can comprise a moiety to facilitate hybridization to its target sequence,
as are known in the art, for example, intercalators and/or minor groove binders.
Variations of the bases, sugars, and intemucleoside backbone, as well as the
presence of any pendant group on the primer, will be compatible with the ability of the
primer to bind, in a sequence-specific fashion, with its target sequence. A large number of
structural modifications, both known and to be developed, are possible within these
bounds. Moreover, synthetic methods for preparing the various heterocyclic bases, sugars,
nucleosides and nucleotides which form the primer, and preparation of oligonucleotides of
specific predetermined sequence, are well-developed and known in the art. A preferred
method for oligonucleotide synthesis incorporates the teaching of U.S. Patent No.
5,419,966.
The oligonucleotide primers can be designed with any special additional moieties or
sequences that will aid and facilitate a particular PCR or subsequent manipulations, e.g.
isolation of the amplified target polynucleotides. For example, a primer can comprise
sequences in addition to those that are complementary to the target sequence. Such
sequences are normally upstream (i.e., to the 5'-side) of the target-complementary
sequences in the primer. For example, sequences comprising one or more restriction
enzyme recognition sites (so-called "linkers" or "adapters"), when present in a primer
upstream of target-complementary sequences, facilitate cloning and subsequent
manipulation of an amplification product. Other useful sequences for inclusion in a primer
include those complementary to a sequencing primer and those specifying a promoter for a
bacteriophage RNA polymerase, such as, for example, T3 RNA polymerase, T7 RNA
polymerase and/or SP6 RNA polymerase.
In one aspect of the invention, the microarray primers are defined by a tiling
method to cover an entire region of interest in the target polynucleotide. For example, a
first group of primers are designed so that the sequence of each primer therein corresponds
to the most 5'-portion of the region of interest; a second group of primers have sequence
that is "shifted" from the first group by one nucleotide towards the 3'-end of the region;
and a third group of primers have sequence that is "shifted" from the second group by one
nucleotide toward the 3'-end of the region, and etc. In theory, then, the number of groups
of primers equals to the number of nucleotides in the region of interest. Of course, within
each group of primers that correspond to a particular portion of the region, there are at least
four sets of primers with four different 3'-ends as described above. When multiple target
polynucleotides are to be detected according to the present invention, each primer group
corresponding to a particular target polynucleotide is resided in a discrete area of the
microarray.
2. Solid Phase Support
The solid phase support of the present invention can be of any solid materials and
structures suitable for supporting nucleotide hybridization and synthesis. Preferably, the
solid phase support comprises at least one substantially rigid surface on which the primers
can be immobilized and the PCR reaction performed. The solid phase support can be made
of, for example, glass, synthetic polymer, plastic, hard non-mesh nylon or ceramic. Other
suitable solid support materials are known and readily available to those of skill in the art.
The size of the solid support can be any of the standard microarray sizes, useful for DNA
microarray technology, and the size may be tailored to fit the particular machine being used
to conduct a reaction of the invention. Methods and materials for derivatization of solid
phase supports for the purpose of immobilizing oligonucleotides are known to those skill in
the art and described in, for example, U.S. Pat. No. 5,919,523, the disclosure of which is
incorporated herein by reference.
The solid support can be provided in or be part of a fluid containing vessel. For
example, the solid support can be placed in a chamber with sides that create a seal along the
edge of the solid support so as to contain the polymerase chain reaction (PCR) on the
support In a specific example the chamber can have walls on each side of a rectangular
support to ensure that the PCR mixture remains on the support and also to make the entire
surface useful for providing the primers.
3. Primer Immobilization
The oligonucleotide primers of the invention are affixed, immobilized, provided,
and/or applied to the surface of the solid support using any available means to fix,
immobilize, provide and/or apply the oligonucleotides at a particular location on the solid
support. For example, photolithography (Affymetrix, Santa Clara, CA) can be used to
apply the oligonucleotide primers at particular position on a chip or solid support, as
described in the U.S. patents, U.S. Pat. No. 5,919,523, U.S. Pat. No. 5,837,832, U.S. Pat.
No. 5,831,070, and U.S. Pat. No. 5,770,722, which are incorporated herein by reference.
The oligonucleotide primers may also be applied to a solid support as described in Brown
and Shalon, U.S. PAT. NO. 5,807,522 (1998). Additionally, the primers may be applied to
a solid support using a robotic system, such as one manufactured by Genetic MicroSystems
(Woburn, MA), GeneMachines (San Carlos, CA) or Cartesian Technologies (Irvine, CA).
D. Detecting Sequence Variations in a Target Polynucleotides
In one aspect of the invention, solid phase amplification of target polynucleotides
from one biological sample is performed, wherein multiple groups of oligonucleotide
primers are immobilized on a solid phase support. In a preferred embodiment, the primers
within a group comprises at least a first set of primers that are identical in sequence and are
complementary to a defined sequence of the target polynucleotide, capable of hybridizing
to the target polynucleotide under appropriate conditions, and suitable as initial primers for
nucleic acid synthesis (i.e., chain elongation or extension). Selected primers covering a
particular region of the reference sequence are immobilized, as a group, onto a solid
support at a discrete location. Preferably, the distance between groups is greater than the
resolution of detection means to be used for detecting the amplified products. In a preferred
embodiment, the primers are immobilized to form a microarray or chip that can be
processed and analyzed via automated processing. The immobilized primers are used for
solid phase amplification of target polynucleotides under conditions suitable for a nucleic
acid amplification means.
According to one aspect of the invention, the initial target polynucleotide is in
double-stranded form with a sense strand ("positive strand") and a complementary strand
("negative strand"). Prior to conducting amplification, the target polynucleotide undergoes
denaturation, such as thermal denaturation, whereby the two strands are denatured and
separated in the reaction solution. Preferably, primers used in the invention are in vast
molar excess to the estimated concentration of the target polynucleotides to counteract the
renaturation of the two target polynucleotide strands. Alternatively, the initial target
polynucleotide is a single-strand, be it a single-stranded DNA or RNA.
In one preferred embodiment of the invention, the nucleic acid amplification is
mediated by a polymerase. More preferably, the amplification is performed under
conditions suitable for a PCR reaction. As understood by those skilled in the art, a PCR
reaction generally involves multiple cycles of annealing-elongating-denaturing steps at
varied reaction temperatures, during which multiple copies of nascent strands are
synthesized based on the initial target polynucleotide as template. As the results, the initial
target sequences are "amplified" either linearly or exponentially, depending on the
condition and restraints of the PCR reaction.
During the PCR reaction according to the present invention, the array of
immobilized primers are contacted with the target polynucleotide in a reaction mixture,
following denaturation if the target polynucleotides are in double-stranded form. Under
conditions suitable for annealing, the single stranded target polynucleotide is hybridized to
an immobilized single primer which contains sequence complementary to a defined
sequence region within the single-stranded target polynucleotide. Under conditions suitable
for chain elongation (including but not limited to, the presence of DNA polymerase and
free nucleotides dNTPs), each target polynucleotide strand serves as an initial template for
synthesis of a nascent complementary strand, which is primed from the 3'-hydroxyl of the
annealed primer and extended to the 5'-end of the target template. Following the
completion of chain elongation, the reaction condition is changed to allow denaturation,
during which the target strand and the nascent strand are separated so that the target strand
is released into the sample solution and the nascent strand retained on the solid support via
the immobilized primer.
In practicing the present invention, the immobilized single primers can be used
alone or, alternatively, in combination with primers in the reaction solution that are
complementary to the sequence at the 3'-end of the nascent immobilized strands.
Furthermore, the solution phase primers can be either universal primers capable of
amplifying all the target polynucleotides or, a pool of specific primers, each of which is
specific to a particular target sequence.
In one aspect of the invention, there are no solution phase primers used.
Accordingly, the initial amplification reaction as described above produces nascent strands
affixed to the solid phase support at each primer site, either as a single strand or annealed
with an initial target polynucleotide strand, depending upon whether or not a denaturation
step is introduced after elongation. And the presence of these nascent strands can be
detected by appropriate detection means as further described below.
In another aspect of the invention, solution phase primers are used in combination
with the solid phase immobilized primers for the amplification of the multiple target
polynucleotides. Subsequent to the initial amplification reaction, another round of
amplification reaction is performed, during which the previously formed nascent strand
complementary at its 3'-end to the solution phase primers will anneal to the solution phase
primers and serve as a template for a subsequent synthesis of a second nascent strand
substantially identical to the target polynucleotide. As the result, a double-stranded nascent
polynucleotide can be formed and affixed on the solid phase support at each primer site.
For the purpose of the invention, target polynucleotides can be double stranded
DNA, single stranded DNA, or RNA. Examples of target polynucleotide include, but are
not limited to, genomic DNA, cDNA, mRNA, mitochondria DNA, viral DNA, amplified
DNA, and viral RNA. Double-stranded target polynucleotides undergo denaturation at the
beginning of the amplification reactions to provide single-stranded templates.
mRNA target polynucleotides can be directly used as templates for amplification
mediated by reverse transcriptase. Following the completion of chain elongation originated
from each immobilized primer site, the hybridized RNA template strand can be destroyed
by, for example, RNAse H, leaving the nascent complementary DNA strand affixed to the
solid phase support. If a second primer (either specific or universal) is present in the
solution phase, the first nascent cDNA strand will serve as a template for synthesizing
another nascent strand, thereby forming a double-stranded nascent DNA molecule at each
immobilized primer site or binding two immobilized primers.
Alternatively, mRNA target polynucleotides in a sample can be first reverse-
transcribed into complementary DNAs which in turn serve as initial templates for the solid
phase PCR reactions of the invention. The reverse transcription can be initiated from, for
example, a poly-T universal primer that can also be used as the universal primer in solution
phase for a PCR amplification reaction according to the invention. A poly-T initiated
cDNA product will anneal at its 3'-end to the specific primer immobilized on the solid
phase support and serves as template for subsequent synthesis of a nascent complementary
strand having at its 3'-end a poly-A sequences. Following a denaturation step, the single
immobilized nascent strand is capable of hybridizing to a poly-T universal primer in the
solution phase and serving as template for subsequent round of PCR amplification and
formation of double-stranded nascent polynucleotides that are affixed to the solid phase
support.
Multiple target polynucleotides of the invention can be from one single biological
source or, alternatively, from multiple biological sources such as different species or
tissues. For example, a population of target polynucleotides isolated from a healthy
individual can be mixed in one PCR reaction with another population of target
polynucleotides isolated from a patient with a disease of interest, under conditions that
would allow distinguishing amplified products of the two sources by detection methods
known in the art, as described in detail above. Therefore, the present invention can be used
for a cross-species comparative analysis of target polynucleotides.
5. PCR Reaction
In practicing the invention, a reaction mixture comprising the appropriate target
polynucleotides mixed with the reagents necessary for conducting the polymerase chain
reaction (PCR) are placed in contact with each immobilized primer pair or single primer
population on the solid support. The appropriate target polynucleotides can be double
stranded DNA, single stranded cDNA generated by reverse transcription of RNA templates,
or mRNA population. The reaction mixture contains an enzyme for facilitating the
synthesis of a polynucleotide strand complementary to a target strand, e.g. a polymerase.
Suitable polymerases include thermostable polymerase enzymes, such as a Taq DNA
polymerase, Tthl DNA polymerase, Vent DNA polymerase, and Pfu DNA polymerase.
The reaction mixture can also contain a label molecule capable of being incorporated into
the nascent strands during polymerase chain reaction so that the amplified products can be
detected on the solid support after the PCR. The label can be detected directly or indirectly
according to methods well known in the art Suitable labels for direct detection can be any
fluorescent molecules such as fluorescein isothiocyanate, Texas red or rhodamine.
Molecules facilitating indirect detection, such as biotin or digoxigenin, can also be
incorporated into the nascent strands during the PCR. Biotin can be subsequently detected
by binding to a labeled streptavidin or a labeled anti-biotin antibody. Likewise,
incorporated digoxigenin can be detected by a labeled or unlabeled anti-digoxigenin
antibody, and the unlabeled anti-digoxigenin antibody can be detected by binding a labeled
anti-anti-digoxigenin antibody.
After the reagents for conducting the PCR contact the immobilized primers on the
microarray, the microarray is placed in conditions that facilitate the PCR to take place,
using for example an automated system such as an in situ PCR machine. The reaction
conditions for the PCR procedure can be as recommended by the in situ PCR machine
manual, and may be varied as appropriate given the nature of the templates being used or
any other difficulties anticipated with the primers and template hybridization.
Temperatures and number of cycles can be selected as recommended and as appropriate
given the primer selection and the template sequences, and any other relevant factors. The
in situ-type PCR reactions on the microarrays can be conducted essentially as described in
e.g. Embretsoneta!, Nature 362:359-362 (1993); Gosdenetal, BioTechniques 15(l):78-80
(1993); Heniford etalNuc. Acid Res. 21 (14):3159-3166 (1993); Long etal, Histochemistry
99:151-162 (1993); Nuovo etal, PCR Methods and Applications 2(4):305-312 (1993);
Patterson et al Science 260:976-979 (1993).
6. Labeling and Detection
The PCR methods of the invention provide for detection of multiple target
polynucleotides in a sample. After the PCR is completed in the presence of appropriate
labeling reagents, the amplified and labeled target polynucleotides can be detected at each
of the original primer locations on the microarray. Detecting the amplified or labeled target
polynucleotides can be conducted by standard methods used to detect the labeled
sequences, including for example, detecting labels that have been incorporated into the
amplified or newly synthesized DNA strands. Thus, for example fluorescent labels or
radiolabels can be detected directly. Other labeling techniques may require that a label such
as biotin ordigoxigenin that is incorporated into the DNA during strand synthesis be
detected by an antibody or other binding molecule (e.g. streptavidin) that is either labeled
or which can bind a labeled molecule itself, for example, a labeled molecule can be e.g. an
anti-streptavidin antibody or anti-digoxigenin antibody conjugated to either a fluorescent
molecule (e.g. fluorescein isothiocyanate, Texas red and rhodamine), or conjugated to an
enzymatically activatable molecule. Whatever the label on the newly synthesized
molecules, and whether the label is directly in the DNA or conjugated to a molecule that
binds the DNA (or binds a molecule that binds the DNA), the labels (e.g. fluorescent,
enzymatic, chemilurninescent, or colorimetric) can be detected by a laser scanner or a CCD
camera, or X-ray film, depending on the label, or other appropriate means for detecting a
particular label.
The target polynucleotide can be detected by using labeled nucleotides (e.g. dNTP-
fluorescent label for direct labeling; dNTP-biotin or dNTP-digoxigenin for indirect
labeling) are incorporated into amplified DNA during the PCR. For indirectly labeled
DNA, the detection is carried out by fluorescence or other enzyme conjugated streptavidin
or anti-digoxigenin antibodies. The PCR method employs detection of the polynucleotides
by detecting incorporated label in the newly synthesized complements to the
polynucleotide targets. For this purpose, any label that can be incorporated into DNA as it
is synthesized can be used, e.g. fluoro-dNTP, biotin-dNTP, or digoxigenin-dNTP, as
described above and are known in the art PCR amplification conducted using one or more
universal primers in solution provides the option to detect the amplified targets at locations
on the solid support by detecting the universal primers. Thus, where more than one
universal primer is used, target strands from different sources can be differentially detected
on the solid support.
In a differential expression system, amplification products derived from different
biological sources can be detected by differentially labeling the amplified strands based on
their origins, as described in the section under "C. Comparing Differential Expression of
Genes from Different Biological Sources." In one aspect, the detection methods used herein
are different from the detection method for single-source targets, in that the differential
labels (e.g., red dye and green dye) are pre-incorporated on the primer tags in solution,
rather than being incorporated into the nascent strands during the amplification.
Alternatively, a third label can also be incorporated into the nascent strand during
amplification, in addition to the differential labels, so that the overall sensitivity for
differential expression comparison is enhanced.
7. Detection Kits
The invention provides kits for practicing the methods of the invention. The kit can
include, e.g. the materials and reagents for detecting a plurality of target polynucleotides
that are otherwise difficult to detect on a solid support. The kit can include e.g. a solid
support, oligonucleotide primers for a specific set of target polynucleotides, polymerase
chain reaction reagents and components, e.g. enzymes for DNA synthesis, labeling
materials, and other buffers and reagents for washing. The kit may also include instructions
for use of the kit to amplify specific targets on a solid support. Where the kit contains a
prepared solid support having a set of primers already fixed on the solid support, e.g. for
amplifying a particular set of target polynucleotides, the design and construction of such a
prepared solid support is described above. Such solid supports can be custom-made for
individual kits depending on the target polynucleotides the customer desires to detect. The
kit also includes reagents necessary for conducting a PCR on a solid support, for example
using an in situ-type or solid phase type PCR procedure where the support is capable of
PCR amplification using an in situ-type PCR machine. The support can be contacted with
the reagents for PCR. A sample potentially containing multiple target polynucleotides is
added to the PCR reagent mixture before the reaction. The PCR reagents include the usual
PCR buffers, a thermostable polymerase (e.g. Taq DNA polymerase), nucleotides (e.g.
dNTPs), and other components and labeling molecules (e.g. for direct or indirect labeling
as described above). The solid support provides the affixed primers in designated locations
on the solid support. For conducting the PCR, the support with the immobilized primers is
contacted with reagents for conducting PCR and the target polynucleotide templates in a
reaction mix and the subjected to PCR (e.g. in situ type or solid phase type PCR)
conditions. The instructions for use of the kits can include, e.g. such details for the
procedure as indicated in the description of the methods above. The kits can be assembled
to support practice of the PCR amplification method using immobilized primers alone or,
alternatively, together with solution phase primers.
D. High Throughput Assay of Multiple Target Polynucleotides
The amplification methods described above can be used for a high throughput assay
of multiple target polynucleotides on a single solid phase support. Multiple groups of
primers, either in single form or in pairs, are immobilized onto a solid phase support to
form a microarray with predetermined pattern. Each group of primers correspond to a
particular target polynucleotide and occupies a discrete position within the microarray.
When a sample containing or suspected of containing multiple target polynucleotides is in
contact with the microarray under reaction conditions suitable for PCR reactions as
described above, each target polynucleotide will be amplified and affixed at a discrete
position with the microarray having corresponding primers immobilized thereto.
According to the invention, the number of potential target polynucleotides is limited
only by the available technology for producing and analyzing small dense microarrays. For
example, using known technologies up to about 100,000 polynucleotides may be analyzed
on a single solid support by providing up to about 100,000 different groups of primer pairs
at discrete locations on the solid support, and contacting the support with a PCR solution
and a sample comprising at least one copy of the target polynucleotides that the primers are
designed to detect.
EXAMPLES
Example 1. PCR Detection of the G3PDF gene on Microarrays
A gene encoding human G3PDH was selected for detection by amplification on a
microarray, either by a symmetric PCR in which both members of a primer pair are
immobilized onto the support, or by an asymmetric PCR in which one member of the
primer pair is immobilized and another member is in solution.
Based on the known sequence of human G3PDH (hGSPDH), four sets of primers
were designed and used for the assay. The four sets of primers have identical hG3PDH
gene sequence except for the last base at their most 3'-end, where each set has a different
nucleotide, A, T, C, or G. The primers were synthesized with a 5'-end modification of
amine to aid in affixing the primers to the solid support. The primers were spotted in pairs
or as single primers, at different concentrations, on a silanated glass slide purchased from
Sigma Chemicals (St. Louis, MO).
The silanated slides with the provided primers were hydrated overnight in saturated
NaCl chamber at room temperature. The hydrated slides were rinsed with 4X SSC for 5
minutes and then washed with water. The slides were blocked with SurModics (Madison,
WI) blocking solution (with 0.1% SDS) for 15 minutes at 50°C, and then rinsed with water
2X and dried by air. The slides were then ready for use.
The PCR reaction solution was prepared to give a final concentration at 200 jiM
each dATP, dGTP, and dTTP; 100 uM dCTP and 100 uM Biotin-14-dCTP. The reaction
solution also contains IX Taq reaction buffer (with 1.5 mM MgCl2); human G3PDH gene
plasmids as DNA templates (100 ng phagemid DNA or 500 ng ss-cDNA library) and 2.5
units of Taq polymerase enzyme. 70 ul reaction solutions was generated as follows:

After the PCR was completed, the slide was blocked with a digoxigenin-blocking
solution from Boehringer Mannheim (Indianapolis, Indiana) for 30 minutes at room
temperature. The slide was stained with Streptavidin (5u.g/ul) (1:250 dilution with
digoxigenin-blocking solution) for 30 minutes at room temperature with gentle shaking.
Digoxigenin-washing buffer was used to wash the slide for 15 minutes at room
temperature, twice. The slide was blocked with digoxigenin-blocking solution for 30
minutes at room temperature.
The slide was incubated with the first antibody (rabbit anti-streptavidin) diluted
1:100 in digoxigenin-blocking solution for 1 hour at room temperature. The slide was
washed with digoxigenin-washing buffer for 15 minutes at room temperature, twice. The
slide was incubated with the second antibody (Cy3 conjugated goat anti-rabbit antibody)
diluted 1:100 in digoxigenin-blocking solution for 30 minutes at room temperature. The
slide was washed with digoxigenin-washing buffer for 15 minutes at room temperature,
twice. The slide was scanned with green beam from Genetic MicroSystems, GMS418.
The results of the symmetric PCR is shown in Figure 2.50 ng of G3PDH DNA
fragments were used as PCR templates and the primer concentrations from column 1
through 6 were 250,125,62,31,15 and 7.8 pmol/ul respectively. PCR was carried out
under standard protocol for 15 cycles in the presence of biotinylated dCTP and the signal
was detected using Strepavidin and Cy3 conjugated antibodies. The iUuminated spots
indicate successful amplification of the hG3PDH template at the spots where the wild type
hG3PDH primers having a C residue at the 3'-end are immobilized. In contrast, no
detection of the target hG3PDH template is detectable at any spots where hG3PDH primers
i with different 3 '-end nucleotides were immobilized.
All publications and patent applications cited in this specification are hereby
incorporated by reference as if each individual publication or patent application were
specifically and individually indicated to be incorporated by reference in their entirety.
Although the foregoing invention has been described in some detail by way of
i illustration and example for purposes of clarity of understanding, it will be readily apparent
to those of ordinary skill in the art in light of the teachings of this invention that certain
changes and modifications may be made thereto without departing from the spirit or scope
of the appended claims.
CLAIMS
What is claimed is:
1. A method for identifying sequence variations in a target polynucleotide in a
sample as compared to a reference sequence, the method comprising the steps of:
a) contacting an array of one or more groups of oligonucleotide primers with a
reaction mixture containing the sample and reagents for polymerase-mediated
polynucleotide amplification, wherein the array of oligonucleotide primers is immobilized
on a solid phase support by the 5'- ends of the oligonucleotides, and further wherein each
group of oligonucleotide primers is selected to span a particular region of the reference
sequence, occupy a discrete area on the array, and comprise at least two sets of primers: 1)
a first set that is exactly complementary to the reference sequence; and 2) one or more
additional sets, each of which is identical to the first set of primers but for the nucleotide at
the 3'- end which is different in each additional set;
b) performing polymerase-mediated polynucleotide amplification, whereby the
target polynucleotide serves as template for the synthesis of detectable nascent
polynucleotides which are extended from the sets of primers that are exactly
complementary to the target polynucleotide;
c) detecting the presence of synthesized polynucleotides which are captured on
discrete areas of the solid phase support via corresponding immobilized primers; and
d) identifying sequence variations in the target polynucleotide according to a
detected pattern of synthesized polynucleotides on the solid phase support.
2. The method of claim 1, wherein the reaction mixture further comprises a
population of solution phase primers.
3. The method of claim 2, wherein the population of solution phase primers
includes an universal primer.
4. The method of claim 3, wherein the universal primer is an oligo-dT primer.
5. The method of claim 3, wherein the universal primer is a primer containing
a T7 promoter, a T3 promoter or an SP6 promoter.
6. The method of claim 2, wherein the population of solution phase primers
includes multiple primers each having specific sequences.
7. The method of claim 2, wherein the at least two different target
polynucleotides are from different biological sources.
8. The method of claim 1, wherein the reaction mixture comprises a detectable
label that is incorporated into the nascent polynucleotides, thereby making the nascent
polynucleotides detectable.
9. The method of claim 8, wherein the detectable label is a fluorescent
molecule.
10. The method of claim 8, wherein the detectable label is at least one of
radiolabeled-dNTP, fluoro-dNTP, biotinylated dNTP or a digoxigenin-dNTP.
11. The method of claim 8, wherein the detectable label is conjugated to a
molecule that binds the nascent polynucleotide.
12. The method of claim 11 wherein the detectable label is conjugated to a
molecule that binds a second label incorporated into the nascent polynucleotide.
13. The method of claim 1, wherein the array comprises from at least about 100
to at least about 100,000 groups of immobilized oligonucleotide primers.
14. The method of claim 13, wherein the array comprises at least about 1,000
groups of immobilized oligonucleotide primers.
15. The method of claim 14, wherein the array comprises at least about 10,000
groups of immobilized oligonucleotide primers.
16. The method of claim 1, wherein the solid phase support is made of material
selected from the group consisting of glass, plastics, synthetic polymers, ceramic and
nylons.
17. The method of claim 1, wherein the polymerase is Taq polymerase, TthI
polymerase, Vent polymerase, Pfu polymerase or any other thermostable polymerase.
18. A kit for identifying sequence variations in a target polynucleotide as
compared to a reference sequence, comprising:
a) an array of multiple groups of oligonucleotide primers immobilized to a solid
phase support, wherein each group of oligonucleotide primers is selected to span a
particular region of the reference sequence, occupying a discrete area of the array, and
comprising at least four sets of primers: 1) a first set that is exactly complementary to the
reference sequence; and 2) three additional sets of primers, each of which is identical to the
first set of primers but for the nucleotide at the 3'- end, which is different in each of the
three sets;
b) reagents suitable for a polymerase-mediated polynucleotide amplification
reaction on the array; and
c) detection means for detecting amplified polynucleotides on the array.
19. The kit of claim 18, wherein the detection means comprises a detectable
label that is incorporated into the amplified polynucleotides during the amplification
reaction.
20. The kit of claim 19, wherein the detectable label is a fluorescent molecule.
21. The kit of claim 19, wherein the detectable label is a biotinylated 11 -dNTP
or a digoxigenin-dNTP.
22. An array for identifying sequence variations in a target polynucleotide in a
sample as compared to a reference sequence by polymerase-mediated polynucleotide
amplification, the array comprising:
one or more groups of oligonucleotide primers immobilized on discrete areas of a
solid phase support, wherein the group of oligonucleotide primers is selected to span a
particular region of the reference sequence, each group comprising:
at least two sets of primers wherein 1) a first set is exactly complementary to the
reference sequence, and 2) each of one or more additional sets is identical to the first set of
primers except for the nucleotide at the 3'- end which is different in each additional set,
such that the target polynucleotide serves as template for the synthesis of detectable nascent
polynucleotides extended from the sets of primers that are exactly complementary to the
target polynucleotide.
23. The method of claim 22, wherein the array comprises from at least about
100 to at least about 100,000 groups of immobilized oligonucleotide primers.
24. The method of claim 23, wherein the array comprises at least about 1,000
groups of immobilized oligonucleotide primers.
25. The method of claim 24, wherein the array comprises at least about 10,000
groups of immobilized oligonucleotide primers.
26. The method of claim 22, wherein the solid phase support is made of material
selected from the group consisting of glass, plastics, synthetic polymers, ceramic and
nylons.
27. The method of claim 22, wherein the array of oligonucleotide primers is
suitable for identifying sequence variations in two or more target polynucleotides.

Solid phase polymerase-mediated amplification approaches using immobilized primers on a microarray are provided
for detecting sequence variations in a target polynucleotide. The methods and compositions provided herein are useful for research
and clinical applications, particularly for large scale assays of genetic information in biological samples of interest.

Documents

Application Documents

# Name Date
1 in-pct-2001-1223-kol-specification.pdf 2011-10-08
2 in-pct-2001-1223-kol-priority document.pdf 2011-10-08
3 in-pct-2001-1223-kol-gpa.pdf 2011-10-08
4 in-pct-2001-1223-kol-form 5.pdf 2011-10-08
5 in-pct-2001-1223-kol-form 3.pdf 2011-10-08
6 in-pct-2001-1223-kol-form 2.pdf 2011-10-08
7 in-pct-2001-1223-kol-form 18.pdf 2011-10-08
8 in-pct-2001-1223-kol-form 1.pdf 2011-10-08
9 in-pct-2001-1223-kol-examination report.pdf 2011-10-08
10 in-pct-2001-1223-kol-drawings.pdf 2011-10-08
11 in-pct-2001-1223-kol-description (complete).pdf 2011-10-08
12 in-pct-2001-1223-kol-correspondence.pdf 2011-10-08
13 in-pct-2001-1223-kol-claims.pdf 2011-10-08
14 in-pct-2001-1223-kol-assignment.pdf 2011-10-08
15 in-pct-2001-1223-kol-abstract.pdf 2011-10-08
16 in-pct-2001-1223-kol-abandonment letter.pdf 2011-10-08